360b / Shutterstock.com
Allergan and MedImmune have entered into a $1.52 billion licensing agreement under which Allergan has gained the global rights to develop MEDI2070, which treats inflammatory disorders.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Allergan, MedImmune, AstraZeneca, MEDI2070, biologics, licensing agreement